Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial

被引：0

作者：

Pressiani, T. ^{[1
]}

Balsano, R. ^{[2
]}

Giordano, L. ^{[3
]}

Milella, M. ^{[4
,5
]}

Bergamo, F. ^{[6
]}

Bozzarelli, S. ^{[7
]}

Noventa, S. ^{[8
]}

Ferrari, D. ^{[9
]}

Scartozzi, M. ^{[10
,11
]}

Parra, H. J. Soto ^{[12
]}

Auriemma, A. ^{[4
,5
]}

Solda, C. ^{[13
]}

Zaniboni, A. ^{[8
]}

Zecchetto, C. ^{[4
,5
]}

Rizzato, M. D. ^{[6
]}

Rimassa, L. ^{[14
]}

Santoro, A. ^{[15
]}

机构：

[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy

[2] Humanitas Univ, IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Dept Biomed Sci,Humanitas Canc Ctr, Rozzano, Italy

[3] IRCSS Humanitas Res Hosp, Biostat Unit, Humanitas Canc Ctr, Rozzano, Italy

[4] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med DIMI, Oncol Area, Verona, Italy

[5] Verona Univ & Hosp Trust, Verona, Italy

[6] IRCCS, Veneto Inst Oncol IOV, Dept Oncol, Oncol 1, Padua, Italy

[7] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy

[8] Fdn Poliambulanza Ist Osped, Med Oncol Unit, Brescia, Italy

[9] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol Dept, Med Oncol & Hematol Unit,AO S Paolo, Milan, Italy

[10] Univ Monserrato, Med Oncol, Monserrato, Italy

[11] Univ Hosp, Monserrato, Italy

[12] Azienda Osped Univ Policlin San Marco, Oncol Med, Catania, Italy

[13] IRCCS, Veneto Inst Oncol IOV, Oncol 1, Dept Oncol, Padua, Italy

[14] Humanitas Univ, Med Oncol & Hematol Unit, Dept Biomed Sci, Humanitas Canc Ctr,IRCCS Humanitas Res Hosp, Rozzano, Italy

[15] Humanitas Univ, Med Oncol & Hematol Unit, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Rozzano, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

285P

引用

页码：S120 / S120

页数：1

共 50 条

[1] Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
Pressiani, Tiziana
Balsano, Rita
Giordano, Laura
Milella, Michele
Bergamo, Francesca
Bozzarelli, Silvia
Noventa, Silvia
Ferrrari, Daris
Scartozzi, Mario
Parra, Hector Soto
Auriemma, Alessandra
Solda, Caterina
Zaniboni, Alberto
Zecchetto, Camilla
Rizzato, Mario Domenico
Rimassa, Lorenza
Santoro, Armando
EUROPEAN JOURNAL OF CANCER, 2024, 207
[2] A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
Liu, Ting
Li, Qing
Lin, Zhen
Liu, Chunhua
Pu, Wei
Zeng, Shasha
Lai, Jun
Cai, Xuebin
Zhang, Lisha
Wang, Shuyang
Chen, Miao
Cao, Wei
Gou, Hongfeng
Zhu, Qing
CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 602 - 615
[3] Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.
Mahipal, Amit
Springett, Gregory M.
Burke, Nancy
Neuger, Anthony
Almhanna, Khaldoun
Wapinsky, Georgine
Bertels, Barbara
Kim, Richard D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Du, J.
Tong, F.
Sha, H.
Sun, Y.
Zhu, Y.
Qi, L.
Li, X.
Li, W.
Yang, Y.
Li, Z.
Xu, C.
Ni, J.
Zhang, X.
Zhu, C.
Wang, X.
Qian, X.
Liu, B.
ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1535
[5] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
Gedela, Sandeep
Munot, Pritesh
Vaidyanathan, Arvind
Joarder, Ritam
Chaugule, Deepali
Parulekar, Manali
Nashikkar, Chaitali
Ghadi, Aayushi
Vadodaria, Divya
Goel, Mahesh
Patkar, Shraddha
Mandavkar, Sarika
Ramaswamy, Anant
Bhargava, Prabhat
Srinivas, Sujay
Ostwal, Vikas
JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 263 - 269
[6] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
Sandeep Gedela
Pritesh Munot
Arvind Vaidyanathan
Ritam Joarder
Deepali Chaugule
Manali Parulekar
Chaitali Nashikkar
Aayushi Ghadi
Divya Vadodaria
Mahesh Goel
Shraddha Patkar
Sarika Mandavkar
Anant Ramaswamy
Prabhat Bhargava
Sujay Srinivas
Vikas Ostwal
Journal of Gastrointestinal Cancer, 2024, 55 : 263 - 269
[7] Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
Huh, Gunn
Choi, Jin Ho
Lee, Sang Hyub
Chun, Jung Won
Cho, In Rae
Paik, Woo Hyun
Ryu, Ji Kon
Kim, Yong-Tae
Lee, Hee Seung
Bang, Seungmin
ANNALS OF ONCOLOGY, 2021, 32 : S287 - S287
[8] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
Kokkali, Stefania
Tripodaki, Elli-Sophia
Drizou, Maria
Stefanou, Dimitra
Magou, Elpida
Zylis, Dimosthenis
Kapiris, Matthaios
Nasi, Despoina
Georganta, Chara
Ardavanis, Alexandros
IN VIVO, 2018, 32 (03): : 653 - 657
[9] Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
Sahai, Vaibhav
Catalano, Paul J.
Zalupski, Mark M.
Lubner, Sam Joseph
Menge, Mark R.
Nimeiri, Halla Sayed
Munshi, Hidayatullah G.
Benson, Al Bowen, III
O'Dwyer, Peter J.
JAMA ONCOLOGY, 2018, 4 (12) : 1707 - 1712
[10] A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer
Noel, Marcus Smith
Allen, Jill N.
Abrams, Thomas Adam
Yurgelun, Matthew
Faris, Jason Edward
Goyal, Lipika
Clark, Jeffrey W.
Blaszkowsky, Lawrence Scott
Murphy, Janet E.
Zheng, Hui
Khorana, Alok A.
Connolly, Gregory Clayton
Hyrien, Ollivier
Ng, Kimmie
Borger, Darrell R.
Iafrate, Anthony John
Hezel, Aram F.
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)

← 1 2 3 4 5 →